1. Association between clinically relevant toxicities of pazopanib and sunitinib and the use of weak CYP3A4 and P-gp inhibitors
- Author
-
Ewa Cottura, Florent Puisset, Loic Mourey, Magali Le Goff, Jean Marie Canonge, Pauline Claraz, Selena Guibaud, Damien Pouessel, Camille Vinson, Olivia Pollet, Véronique Pelagatti, Camille Azam, Christine Chevreau, and Catherine Bardies
- Subjects
Oncology ,Drug ,Male ,medicine.medical_specialty ,Indazoles ,media_common.quotation_subject ,030226 pharmacology & pharmacy ,Pazopanib ,03 medical and health sciences ,Drug withdrawal ,0302 clinical medicine ,Pharmacokinetics ,Internal medicine ,Clinical endpoint ,Sunitinib ,Medicine ,Cytochrome P-450 CYP3A ,Humans ,Pharmacology (medical) ,Drug Interactions ,030212 general & internal medicine ,ATP Binding Cassette Transporter, Subfamily B, Member 1 ,media_common ,Aged ,Retrospective Studies ,Pharmacology ,Sulfonamides ,medicine.diagnostic_test ,Dose-Response Relationship, Drug ,business.industry ,General Medicine ,medicine.disease ,Pyrimidines ,Therapeutic drug monitoring ,Toxicity ,Cytochrome P-450 CYP3A Inhibitors ,Female ,business ,medicine.drug - Abstract
Sunitinib and pazopanib, two tyrosine kinase inhibitors (TKI), may be targets of potential pharmacokinetic drug-drug interactions (P-PK-DDIs). While strong cytochrome P4503A (CYP3A4) inhibitors or inducers should cause a clinically relevant modification in plasma TKI concentrations, the effect of weak inhibitors is unknown. The objective of this study was to evaluate the association between weak P-PK-DDI and clinically relevant toxicity in real life. This was a single-center retrospective study including patients treated with sunitinib or pazopanib for any malignancies, for whom a PK-DDI analysis was performed before starting TKI. The primary endpoint was the correlation between P-PK-DDIs and a dose decrease after 1 month of treatment. The secondary endpoint was the correlation between PK-DDIs and drug withdrawal due to toxicity. Seventy-six patients were assessed. A P-PK-DDI with weak CYP3A4 or P-gp inhibition was found in 14 patients. In patients with P-PK-DDI or without, the dose was reduced during the first month in 57.1% and 17.7% (p = 0.003) and the drug withdrawn in 42.8% and 11.3% (p = 0.011), respectively. In multivariate analysis, a significant correlation was found between P-PK-DDI (CYP3A4 and P-gp inhibitors) and dose reduction, and between drug withdrawal and PK-DDI (CYP3A4 inhibitors). P-PK-DDI was correlated with dose reduction and drug withdrawal due to toxicity. The causality of this relationship warrants to be assessed; therefore, therapeutic drug monitoring is necessary in patients treated with TKI.
- Published
- 2019